Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Stella acts as an intermediary. Researcher contact info is never exposed.